Author:
Ladwig Paula M.,Rivard Ann L.,Barbeln Alex,Maus Anthony,Murray David L.,Snyder Melissa R.,Willrich Maria A.V.
Subject
Clinical Biochemistry,Medical Laboratory Technology,Spectroscopy,Microbiology
Reference25 articles.
1. Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms;Ordás;Clin. Pharmacol. Ther.,2012
2. Mechanism of action of certolizumab pegol (CDP870). In vitro comparison with other anti-tumor necrosis factor α agents;Nesbitt;Inflamm. Bowel Dis.,2007
3. Tumor necrosis factor inhibitors: Clinical utility in autoimmune diseases;Willrich;Transl. Res. J. Lab. Clin. Med.,2015
4. Therapeutic drug monitoring and outcome of infliximab therapy in pediatric onset inflammatory bowel disease;Kolho;Front. Pediatr.,2020
5. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: A prospective cohort study;Wilson;BMC Gastroenterol.,2021